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options for HP/EP. [5] Laparoscopic operation is a common surgery option which has been considered as invaluable both in diagnosis and treatment, but it still involves surgical and anesthetic risks to the mothers and their IU pregnancy. Therefore, no invasion medical treatments are proposed. Previous studies have demonstrated that most unruptured and live EP could be successfully managed through local injection of methotrexate (MTX)/potassium chloride (KCL) or in combination with systemic administration of MTX, with the benefits of no general anesthesia and less tubal damage. [6, 7] However, the management of HP is more difficult and complicated than EP due to the desire to preserve the IU pregnancy. The toxic effects of MTX, even locally injection, may associate with spontaneous abortion and congenital abnormality of remaining fetus. [8] Furthermore, life-threatening neutropenia and febrile morbidity had been reported following MTX treatment to EP. [9] To manage HP successfully and to avoid severe systematic complications and adverse effects on IU pregnancy, a novel mode of management with transvaginal ultrasound-guided local injection of absolute ethanol (AE) was employed in this study.
MaterIalS and MethodS

Patients' characteristics
From 2014 to 2017, five patients diagnosed with HP after in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI)-ET or frozen-thawed ET received transvaginal ultrasound-guided local injection of AE at our center. The patients preferred no invasion management for the strong desire to preserve the IU pregnancy. Their condition had been carefully examined as hemodynamically stable and no signs of active vaginal bleeding with the GA ≤7 weeks and unruptured ectopic gestational sac (GS). The basic characteristics of patients were listed in Table 1 .
The level of serum β-HCG 14 days after ET ranged from 742.47 mIU/ml to 4066.00 mIU/ml. In case 1, an IU GS (37 mm × 23 mm) with the visible fetus heartbeat and an ectopic GS (22 mm × 8 mm) in the cervix with affluent surrounding Doppler flow and no visible fetus heartbeat were detected under TVUS 35 days after ET. The level of serum β-HCG was more than 5000.00 mIU/ml (no dilution of the serum sample). In case 2 and case 3, the size of IU GS was 19 mm × 14 mm and 29 mm × 14 mm respectively, while the size of ectopic GS was 15 mm × 8 mm in the right tube and 21 mm × 12 mm in the left tube respectively under TVUS detection on the day of 28 and 31 after ET. The fetus heartbeats of IU and EP were identified in both the cases, with the levels of serum β-HCG 38,800.00 mIU/ml and 70,164.00 mIU/ml, respectively. In case 4, an IU GS (30 mm × 15 mm) with fetus heartbeat and a right adnexal mass (19 mm × 17 mm) with fluid echo and fetus heartbeat were identified 35 days after ET. The level of serum β-HCG was 224,977.00 mIU/ml [ Figures 1 and 2 ]. In case 5, an IU GS (24 mm × 16 mm) and an ectopic GS (14 mm × 12 mm) in the right tube were identified with fetus heartbeats in both sacs 31 days after ET. The level of serum β-HCG was 166,063.00 mIU/ml.
The procedure of transvaginal ultrasound-guided local injection of absolute ethanol
All the risks and benefits were informed to the patients before the treatment. The risks of sclerotherapy with AE are as followings: survived EP GS might need to repeat injection of AE; ruptured ectopic GS during or after treatment requires emergency surgical intervention; and an inadvertent puncture into blood vessels in the vicinity of the ectopic GS could cause severe internal hemorrhage. The benefits include the avoid of surgery and general anesthesia and no need for hospitalization as well as less cost. All the patients had been provided informed consent after counseling. All the operations were performed by a chief physician. The study was approved by the Reproductive Medical Ethics Committee of the 105 th Hospital of the People's Liberation Army (Approval No.2014A012 was obtained on 1 st February in 2014).
The vulva and vagina were prepared with sterile saline solution, and then, a 17G needle (Queensland, Australia) was used to puncture into the ectopic GS under TVUS guidance (GE Logiq 5 PRO, Gyeonggi, Korea). After suctioning the contents of the GS, 1.0 ml-2.5 ml AE was injected into GS based on the size of GS and the volume of the contents suctioned. The whole time of this procedure took <10 min without anesthesia. After injection of AE, a high-intensity image in injected site was observed under transvaginal ultrasound. All patients were monitored for 3 h after the procedure.
reSultS
All the patients tolerated the procedure well. In cases 1-4, the size of ectopic GS shrank or disappeared and a high-intensity image in the injected site was observed. No fetal heartbeat was visualized on the 3 rd day postoperation. The follow-up was done for several weeks after injection until no Doppler flow and expansive sign of ectopic GS were identified [ Figure 3 ]. with the serum level of β-HCG 113,208.00 mIU/ml 1 week after the treatment, and a healthy female infant weighing 2050 g delivered at 38 weeks of gestation through the cesarean Their height and body weight were comparable to the children conceived naturally in China. [10] dIScuSSIon HP was first reported by Duverney in 1708, [11] during an autopsy on a patient who had died of a ruptured EP. Early diagnosis is the key to manage HP but remains many challenges. It is acknowledged that patients with symptoms such as abdominal pain, vaginal bleeding, and rectal tenesmus might be diagnosed earlier than those without symptoms. [12, 13] However, these symptoms are rarely seen in HP due to the coexistence of IU pregnancy. Transvaginal ultrasonography has been considered as a valuable tool in early diagnosis of HP. However, GS might be mistaken with a hemorrhagic corpus luteum or ovarian cyst for the patients who underwent ART. [14] Persistent enlargement of adnexal fluid mass with affluent blood flow may be the early ultrasonographic sign of EP. Therefore, even when an IU pregnancy is diagnosed, transvaginal ultrasonic scan should be carefully carried out to rule out HP in ART patients. In our center, the first transvaginal ultrasonography was usually performed on 30-35 days after ET. In this study, all five HP patients were diagnosed HP within 7 weeks of gestation.
The managements of HP mainly include surgery and medical treatment, while the choice remains controversial due to the desire to preserve the IU pregnancy. Local injection medicines such as MTX into EP have been demonstrated successful in managing EP or cesarean scar ectopic pregnancy, [15] with the advantages of being simple, effective, less invasive, and inexpensive, although a combination with systemic MTX administration was needed sometimes. [5] MTX not only can lead to embryonic development arrest but also has various side effects on the mother such as bone marrow suppression, liver enzyme elevation, rash, alopecia, and stomatitis. [14] Therefore, MTX has little value in HP management for its toxic effects on both mother and IU fetus. [16] Other medicines such as KCL and hyperosmolar glucose were also reported in managing HP for avoiding the potential systemic side effects and toxicity to IU pregnancy. [17, 18] However, a case report revealed that the therapeutic effect of KCL might not satisfactory for two of three cases abortive after local injection of KCL, suggesting that KCL might also have adverse effects to IU pregnancy. [19] Studies carried out on the management of heterotopic/EP through local injection are listed in Table 2 .
Laparoscopy and transvaginal ultrasound guidance are two common methods for the local administration of drugs. It had been confirmed that direct intraocular injection under ultrasound guidance was superior to the laparoscopically controlled "blind" intratubal injection. [24] Furthermore, the latter needs carbon dioxide pneumoperitoneum and [20] 69 35 AE EP 0.3 ml 0.3 ml Chen et al., 2011 [21] 17/11 30/31 Etoposide/MTX EP 50 mg -Ugurlucan et al., 2012 [22] 1 34 KCL HP 2 mEq/ml 2 ml Allison et al., 2012 [17] 1 31 Hyperosmolar glucose HP 50% Equal with aspirated Ishikawa et al., 2016 [23] 11 31 Diluted vasopressin EP 4-10 units -MTX: Methotrexate, KCL: Potassium chloride, AE: Absolute ethanol, HP: Heterotopic pregnancy, EP: Ectopic pregnancy general anesthesia, which may have an adverse effect on IU pregnancy. [25] AE is a dehydrating agent which could quickly infiltrate into the chorionic tissue surrounding the GS and then dehydrate and destroy chorionic villi. In 2006, Kaijima et al. [20] first reported this novel management for the patients with EP and found that the serum level of β-HCG decreased 10%-30% within 2 h after the local injection of AE, quicker than MTX (2-3 days). Moreover, patients' financial burdens are alleviated since AE costs less. Some prospective clinical studies had demonstrated that the local injection of AE for the patients with hydrosalpinx could improve the outcomes of IVF with no adverse effect on ovarian reserve and perinatal outcomes. [26, 27] However, local injection of AE for EP was usually carried out at an early stage of GA (5-week gestation age), and the serum β-HCG level was <4000 mIU/mL without fetus heartbeat. [20] Furthermore, the candidates should be hemodynamically stable without the sign of ectopic GS rupture and no contraindications to the agent furthermore, patients should be followed up strictly after the operation and emergency surgery is necessary once there are signs of ectopic GS rupture.
In this study, gestation age of five cases was 6-7 weeks with the level of serum β-HCG ranged from 38,800.00 mIU/ml to 224,977.00 mIU/ml when local injection of AE was carried out, and the size of ectopic GS ranged from 15 mm × 8 mm to 19 mm × 17 mm and visible fetus heartbeats in four cases. Four cases who received local injection of AE delivered healthy live birth, and the babies' physical and psychomotor developments were in the normal range of children conceived naturally in China, [10] indicating that the management of HP with transvaginal ultrasound-guided local injection of AE may not have adverse effects on the IU pregnancy and could be efficiently carried out within 7 weeks of GA.
The dose and concentration of agents are important for effectiveness and safety when medical treatment was carried out. In this study, the dose of AE administrated in four successful cases was all within 2.0 ml, whereas one case received emergency laparoscopic surgery for rupturing of EP when 2.5 ml AE was injected into ectopic GS, suggesting that local injection of overdose AE may lead to a higher risk of ectopic GS rupture. It was also found that the ectopic GS in one case enlarged 2 weeks after injection 1.0 ml AE. After additional injection of 2.0 ml AE being performed, the ectopic GS decreased from 35 mm × 11 mm to 26 mm × 22 mm 1 week later, and no re-expansion and any complication identified afterward. Therefore, the management of HP with transvaginal ultrasound-guided local injection of AE should be carried out in a limited volume (<2.0 ml). If it does not work efficiently, additional injection could be performed. The main limitation of this study is small sample size. In addition, the valid dose and opportunity of AE administration and its effectiveness and safety remain further evaluation through a large randomized controlled trail.
concluSIonS
Transvaginal ultrasound-guided local injections of AE might be served as an alternative option for the management of unruptured HP at a very early stage, with the advantage of less invasive and expensive.
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